KR20220083737A - 혈액 장애를 치료하기 위한 조성물 및 방법 - Google Patents

혈액 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220083737A
KR20220083737A KR1020227015552A KR20227015552A KR20220083737A KR 20220083737 A KR20220083737 A KR 20220083737A KR 1020227015552 A KR1020227015552 A KR 1020227015552A KR 20227015552 A KR20227015552 A KR 20227015552A KR 20220083737 A KR20220083737 A KR 20220083737A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
thrombocytopenia
decreased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227015552A
Other languages
English (en)
Korean (ko)
Inventor
테드 예드녹
세투 산카라나라야난
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20220083737A publication Critical patent/KR20220083737A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227015552A 2019-10-17 2020-10-16 혈액 장애를 치료하기 위한 조성물 및 방법 Pending KR20220083737A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
US62/916,492 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Publications (1)

Publication Number Publication Date
KR20220083737A true KR20220083737A (ko) 2022-06-20

Family

ID=75538375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015552A Pending KR20220083737A (ko) 2019-10-17 2020-10-16 혈액 장애를 치료하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (1) US20240109957A1 (enExample)
EP (1) EP4045084A4 (enExample)
JP (2) JP7809056B2 (enExample)
KR (1) KR20220083737A (enExample)
CN (1) CN114746118A (enExample)
AU (1) AU2020365132A1 (enExample)
BR (1) BR112022007051A2 (enExample)
CA (1) CA3157873A1 (enExample)
IL (1) IL292186A (enExample)
MX (1) MX2022004287A (enExample)
WO (1) WO2021076991A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
AU2021361067A1 (en) * 2020-10-16 2023-06-01 Annexon, Inc. Compositions and methods for treating blood disorders
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
CN106349390B (zh) * 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä

Also Published As

Publication number Publication date
MX2022004287A (es) 2022-07-19
CA3157873A1 (en) 2021-04-22
JP2022551751A (ja) 2022-12-13
AU2020365132A1 (en) 2022-04-28
EP4045084A4 (en) 2023-05-31
EP4045084A1 (en) 2022-08-24
WO2021076991A1 (en) 2021-04-22
US20240109957A1 (en) 2024-04-04
JP2026028257A (ja) 2026-02-19
JP7809056B2 (ja) 2026-01-30
CN114746118A (zh) 2022-07-12
IL292186A (en) 2022-06-01
BR112022007051A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
JP7275223B2 (ja) ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP7809056B2 (ja) 血液障害を処置するための組成物及び方法
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
CN115260310A (zh) 抗补体因子c1q的fab片段及其应用
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
WO2014169076A1 (en) Methods of treatment for neuromyelitis optica
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
CN116782940A (zh) 用于治疗眼部疾病的组合物和方法
KR20230087572A (ko) 혈액 장애를 치료하기 위한 조성물 및 방법
JP2024503724A (ja) 免疫調節抗体およびその使用
JP2024539141A (ja) 筋ジストロフィーを治療するための組成物及び方法
CN115996752A (zh) 用于治疗癫痫的组合物和方法
JP2025515485A (ja) 眼の疾患を治療するための組成物及び方法
HK40077291A (en) Compositions and methods for treating blood disorders
IL278246B2 (en) Using factors that target epithelial membrane protein 2 to treat lung disorders
RU2782950C2 (ru) Подкожное введение анти-cd38 антител
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания
CN119677537A (zh) 用于治疗狼疮性肾炎的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000